Targeted molecular therapy for malignant gliomas

Current Treatment Options in Oncology

Volumn 5, Issue 6, 2004, Pages 519-526

  Nabors, L Burt ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; CRM 107; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; IMATINIB; INTERLEUKIN 13; INTERLEUKIN 4; LEFLUNOMIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PD 184322; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PSEUDOMONAS EXOTOXIN; RAF PROTEIN; SEMAXANIB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SORAFENIB; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; TIPIFARNIB; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB;

ANGIOGENESIS; APHASIA; BRAIN EDEMA; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG TARGETING; GLIOBLASTOMA; HEADACHE; HUMAN; MUSCLE WEAKNESS; NEUROTOXICITY; NONHUMAN; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 9944226684     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0040-4     Document Type: Review

References (48)

1. Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985, 35:219-226.
2. Burger PC, Green SB: Patient age, histological features, and length of survival in patients with glioblastoma multiforme. Cancer, 1987, 59:1617-1625.
3. Maher EA, Furnari FB, Bachoo RM, et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001, 15:1311-1333.
4. Watanabe K, Tachibana O, Sata K, et al.: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996, 6:217-223.
5. Recht L, Torres CO, Smith TW, et al.: Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. Neurosurg 1990, 72:941-945.
6. Greenfield L, Johnson VG, Youle RJ: Mutations in diphtheria toxin separate binding from entry and amplified immunotoxin selectivity. Science 1987, 238:536-539.
7. Laske D, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997, 3:1362-1368.
8. Weaver M, Laske D: Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107 for therapy of malignant glioma. J Neurooncol 2003, 65:3-13.
9. Libermann TA, Nusbaum HR, Razon N, et al.: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985, 313:144-147.
10. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 2001, 94:1593-1611.
11. Crombet T, Osorio M, Cruz T, et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001,20:131-136.
12. Stragliotto G, Vega F, Stasiecki P, et al.: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55900) in patients with recurrent malignant glioma. Eur J Cancer 1996, 32A:636-640.
13. Kuan CT, Wikstrand CJ, Archer G, et al.: Increased binding affinity enhances targeting of glioma xenografts by egfrvIII-specific scFv. Int J Cancer 2000, 88:962-969.
14. Phillips PC: Transforming growth factor alpha Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice Cancer Res, 1994. 54:1008-1015.
15. Sampson J, Akabani G, Archer GE, et al.: Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF-a) and a mutated form of Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Neurooncol 2003, 65:27-35.
16. Puri R: Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the cytotoxic effects of IL-4 Pseudomonas exotoxin chimeric protein. Int J Cancer 1994. 58:574-581.
17. Weber F, Asher A, Bucholz R, et al.: Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003, 64:125-137.
18. Minty A, Chalon P, Derocq JM, et al.: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses Nature 1993, 362:248.
19. Husain S, Joshi BH, Puri R: Interleukin-13 receptor as a unique target for antiglioblastoma therapy. Int J Cancer 2001, 92:168-175.
20. Debinski W, Obiri NI, Pastan I, Puri RK: A novel chimeric protein composed of interleukin-13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing the receptors for interleukin 13 and interleukin 4. J Biol Chem 1995, 270: 6775-16780.
21. Husain S, Puri R: Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003, 65:37-48.
22. Weingart J: Intratumoral convection-enchanced delivery of IL13-PE38QQR cytotoxin for recurrent malignant glioma without planned resection: a phase I/II study. J Neurooncol 2003, 5(4): 57.
23. Kunwar, S: Peritumoral convection-enhanced delivery of IL13-PE38QQR in patients with recurrent malignant glioma - phase I interim results. J Neuroonco, 2003, 5(4): 351.
24. Lyons SA, O'Neal J, Sontheimer H: Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002, 39:162-173.
25. Deshane J, Garner CC, Sontheimer H: Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 2003, 278:4135-4144.
26. Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H, et al.: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998, 58:4871-4879.
27. Mamelak AN: A phase I/II trial of intracavitary 131ITM-601 in adult patients with recurrent high-grade glioma. J Neurooncol 2003, 5:340.
28. Adjei AA, Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062-1074.
29. Guha A, Feldkamp MM, Lau N, et al.: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997, 15:2755-2765.
30. Westermark B, Heldin CH, Nister M: Platelet-derived growth factor in human glioma. Glia 1995, 15:257-263.
31. Yeh HJ, Ruit KG, Wang YX, et al.: Platelet-derived growth factor (PDGF) A-chain gene is expressed by mammalian neurons during development and in maturity. Cell 1991, 64:209-216.
32. von Deimling A, Eibl RH, Ohgaki H, et al.: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992, 52:2987-2990.
33. Wong AJ, Bigner SH, Bigner DD, et al.: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987, 84:6899-6903.
34. Ekstrand AJ, Sugawa N, James CD, Collins VP, et al.: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992, 89: 309-4313.
35. Rich JN: Phase I/II trial of the epidermal growth factor receptor small molecule inhibitor ZD1839 (gefitinib) in patients with first relapse glioblastoma. J Neurooncol 2003, 5:356.
36. Vogelbaum MA: Initial experience with the EGFR tyrosine kinase inhibitor tarceva (OSI-774) for single-agent therapy of recurrent/progressive glioblastoma multiforme. J Neurooncol 2003, 5:356.
37. Buday L, Downward J: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor. Cell 1993, 73: 11-620.
38. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 366:643-654.
39. CloughesyTF: Two phase II trials of R115777 (Zarnestra) in patients with recurrent glioblastoma multiforme (GBM): a comparison of patients on enzyme-inducing anti-epileptic drugs and not on EIAED at maximum tolerated dose respectively. J Neurooncol 2003, 5: 49.
40. Sebolt-Leopold JS: Blockade of the mitogen activated protein (MAP) kinase pathway suppresses growth of colon tumors in vivo Nat Med 1999, 5:810-816.
41. Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 1997, 94: 2479-12484.
42. Wang SI: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997, 57:4183-4186.
43. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 52-364.
44. Ellis LM, Takahashi Y, Liu W, Shaheen RM: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000, 5(Suppl 1):11-15.
45. Reardon DA: Preliminary phase I trial results: PTK787/ZK222584 (PTK/ZK) an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme. J Neurooncol 2003, 5: 55.
46. Groves M, Puduvalli VK, Hess KR, et al.: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor Marimastat in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383-1388.
47. Cheresh D: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attchement to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987, 84:6471-6475.
48. Nabors LB, Rosenfeld R, Mikkelsen T: A phase I trial of EMD 121974 for treatment of patients with recurrent malignant glioma. J Neurooncol 2002, 4:373.